Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
Sumit Poddar, from Tikona Capital, discusses the market correction and predicts a better economic outlook in the upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback